Regulation of community advisory boards during conduct of clinical trials in Uganda: a qualitative study involving stakeholders.
Clinical trials
Community advisory boards
Regulation
Stakeholders Uganda
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
06 Feb 2023
06 Feb 2023
Historique:
received:
09
06
2022
accepted:
31
01
2023
entrez:
5
2
2023
pubmed:
6
2
2023
medline:
8
2
2023
Statut:
epublish
Résumé
Community advisory structures such as Community Advisory Boards (CABs) play an important role of helping researchers to better understand the community at each phase of the clinical trial. CABs can be a source of accurate information on the community, its perception of proposed research and may identify factors that make community members vulnerable to the problem under investigation. Although CABs help to build mutually beneficial relationships between the researcher(s) and the communities in which the clinical trial is being implemented, effective engagement would require ethical guidance and regulatory oversight. The study assessed the stakeholders' perspectives regarding the regulatory oversight of CABs in Uganda. This was an exploratory study employing qualitative methods of data collection and analysis. Key informant interviews (KIIs) with the trial investigators, CAB chairpersons, community liaison officers, regulators and Research Ethics Committee (REC) chairpersons were conducted. A KII guide was designed and utilized during key informant interviews. The guide included questions on role of investigators and CAB members in clinical trials; challenges of community engagement; facilitation of CABs; regulatory oversight of CABs; work relationships between investigators and CABs; and opinions on how community trials should be conducted among others. All interviews were conducted in English. Qualitative data were transcribed verbatim. A code book was generated based on the transcripts and study objectives. Thematic analysis was used to analyze data and identify themes. Atlas ti was used to support data analysis. Of the 34 respondents, 35.3% were investigators, 32.3% CAB chairpersons, 23.5% research regulators/REC Chairs and 8.8% community liaison officers. The findings of the study revealed that CABs are appointed by the research institution/researcher, operate under the guidance of the researcher with limited independence. Additionally, the CABs provide voluntary service and lack guidelines or regulatory oversight. Four themes emerged. The operations and activities of CABs are not regulated by the national regulators or RECs. The regulatory oversight of CABs should be based on contextualized ethical guidelines. Need for additional training in research ethics, community engagement and sensitization on available ethics guidelines for research.
Sections du résumé
BACKGROUND
BACKGROUND
Community advisory structures such as Community Advisory Boards (CABs) play an important role of helping researchers to better understand the community at each phase of the clinical trial. CABs can be a source of accurate information on the community, its perception of proposed research and may identify factors that make community members vulnerable to the problem under investigation. Although CABs help to build mutually beneficial relationships between the researcher(s) and the communities in which the clinical trial is being implemented, effective engagement would require ethical guidance and regulatory oversight. The study assessed the stakeholders' perspectives regarding the regulatory oversight of CABs in Uganda.
METHODS
METHODS
This was an exploratory study employing qualitative methods of data collection and analysis. Key informant interviews (KIIs) with the trial investigators, CAB chairpersons, community liaison officers, regulators and Research Ethics Committee (REC) chairpersons were conducted. A KII guide was designed and utilized during key informant interviews. The guide included questions on role of investigators and CAB members in clinical trials; challenges of community engagement; facilitation of CABs; regulatory oversight of CABs; work relationships between investigators and CABs; and opinions on how community trials should be conducted among others. All interviews were conducted in English. Qualitative data were transcribed verbatim. A code book was generated based on the transcripts and study objectives. Thematic analysis was used to analyze data and identify themes. Atlas ti was used to support data analysis.
RESULTS
RESULTS
Of the 34 respondents, 35.3% were investigators, 32.3% CAB chairpersons, 23.5% research regulators/REC Chairs and 8.8% community liaison officers. The findings of the study revealed that CABs are appointed by the research institution/researcher, operate under the guidance of the researcher with limited independence. Additionally, the CABs provide voluntary service and lack guidelines or regulatory oversight. Four themes emerged.
CONCLUSION
CONCLUSIONS
The operations and activities of CABs are not regulated by the national regulators or RECs. The regulatory oversight of CABs should be based on contextualized ethical guidelines. Need for additional training in research ethics, community engagement and sensitization on available ethics guidelines for research.
Identifiants
pubmed: 36740683
doi: 10.1186/s12913-023-09136-w
pii: 10.1186/s12913-023-09136-w
pmc: PMC9899660
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119Subventions
Organisme : EDCTP
ID : CSA2018ERC-2318
Informations de copyright
© 2023. The Author(s).
Références
BMC Med Ethics. 2014 Feb 17;15:12
pubmed: 24533875
J Empir Res Hum Res Ethics. 2016 Oct;11(4):311-321
pubmed: 27552841
J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 1:S68-74
pubmed: 18724193
BMJ Open. 2020 Apr 30;10(4):e035368
pubmed: 32354781
J Int AIDS Soc. 2018 Oct;21 Suppl 7:e25172
pubmed: 30334604
PLoS Med. 2007 Sep;4(9):e273
pubmed: 17850178
SAHARA J. 2010 Oct;7(3):2-8
pubmed: 21409299
Am J Bioeth. 2020 Jun;20(5):43-56
pubmed: 32364467
Biopreserv Biobank. 2019 Dec;17(6):613-624
pubmed: 31603696
Bull Med Ethics. 2002 Oct;(182):17-23
pubmed: 14983848
Dev World Bioeth. 2015 Apr;15(1):18-26
pubmed: 23725206
Dev World Bioeth. 2018 Dec;18(4):420-428
pubmed: 28872746
BMC Med Ethics. 2021 Dec 15;22(1):165
pubmed: 34911524
BMC Med Ethics. 2015 Apr 12;16:24
pubmed: 25889051
BMC Public Health. 2021 Apr 1;21(1):633
pubmed: 33794820
BMC Med Ethics. 2013 Jun 05;14:23
pubmed: 23738971
Glob Bioeth. 2019 Dec 20;31(1):1-12
pubmed: 32002019
Health Res Policy Syst. 2009 Jun 17;7:16
pubmed: 19534798
BMC Med Ethics. 2015 Jul 01;16:44
pubmed: 26126899
Science. 2000 Aug 18;289(5482):1142-4
pubmed: 10970227
BMC Med Ethics. 2019 Jul 16;20(1):50
pubmed: 31311526
BMC Med Ethics. 2015 Jun 03;16:39
pubmed: 26037507
BMC Med Ethics. 2019 Oct 17;20(1):73
pubmed: 31623624